Johnson & Johnson $JNJ Stock Holdings Decreased by Hunter Perkins Capital Management LLC

Hunter Perkins Capital Management LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 0.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 53,648 shares of the company’s stock after selling 85 shares during the period. Johnson & Johnson makes up 1.9% of Hunter Perkins Capital Management LLC’s holdings, making the stock its 17th biggest holding. Hunter Perkins Capital Management LLC’s holdings in Johnson & Johnson were worth $8,195,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Highline Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $52,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on JNJ shares. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Weiss Ratings reissued a “hold (c+)” rating on shares of Johnson & Johnson in a research note on Saturday, September 27th. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, HSBC increased their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $189.88.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE:JNJ opened at $188.95 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market cap of $455.06 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $189.92. The firm has a 50 day simple moving average of $177.04 and a 200 day simple moving average of $163.18.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.